Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

NCT03782792 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Pustular Psoriasis

Interventions

DRUG: Spesolimab
DRUG: Placebo

Sponsor

Boehringer Ingelheim